CY1106730T1 - Οξα - και θειαδιαζολες και η χρηση τους ως αναστολεις μεταλλοπρωτεϊνασης - Google Patents
Οξα - και θειαδιαζολες και η χρηση τους ως αναστολεις μεταλλοπρωτεϊνασηςInfo
- Publication number
- CY1106730T1 CY1106730T1 CY20071100937T CY071100937T CY1106730T1 CY 1106730 T1 CY1106730 T1 CY 1106730T1 CY 20071100937 T CY20071100937 T CY 20071100937T CY 071100937 T CY071100937 T CY 071100937T CY 1106730 T1 CY1106730 T1 CY 1106730T1
- Authority
- CY
- Cyprus
- Prior art keywords
- thijazes
- beauty
- metal protein
- protein suspensions
- suspensions
- Prior art date
Links
- 230000003796 beauty Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 abstract 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 abstract 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0204159.8A GB0204159D0 (en) | 2002-02-22 | 2002-02-22 | Metalloproteinase inhibitors |
| EP03702791A EP1476438B1 (en) | 2002-02-22 | 2003-02-20 | Oxa- and thiadiazoles and their use as metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106730T1 true CY1106730T1 (el) | 2012-10-24 |
Family
ID=9931543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20071100937T CY1106730T1 (el) | 2002-02-22 | 2007-07-13 | Οξα - και θειαδιαζολες και η χρηση τους ως αναστολεις μεταλλοπρωτεϊνασης |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US7358265B2 (es) |
| EP (1) | EP1476438B1 (es) |
| JP (1) | JP4615864B2 (es) |
| KR (1) | KR101098614B1 (es) |
| CN (1) | CN100351245C (es) |
| AT (1) | ATE360007T1 (es) |
| AU (1) | AU2003205910B2 (es) |
| BR (1) | BR0307899A (es) |
| CA (1) | CA2475867C (es) |
| CY (1) | CY1106730T1 (es) |
| DE (1) | DE60313292T2 (es) |
| DK (1) | DK1476438T3 (es) |
| EA (1) | EA007609B1 (es) |
| ES (1) | ES2286404T3 (es) |
| GB (1) | GB0204159D0 (es) |
| HK (1) | HK1078583A1 (es) |
| HR (1) | HRP20040725A2 (es) |
| IL (1) | IL163413A (es) |
| MX (1) | MXPA04008132A (es) |
| NO (1) | NO330772B1 (es) |
| PL (1) | PL210773B1 (es) |
| PT (1) | PT1476438E (es) |
| RS (1) | RS51354B (es) |
| SI (1) | SI1476438T1 (es) |
| UA (1) | UA78275C2 (es) |
| WO (1) | WO2003070711A1 (es) |
| ZA (1) | ZA200406755B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003227952A1 (en) * | 2003-05-17 | 2004-12-03 | British Biotech Pharmaceuticals Ltd | Metalloproteinase inhibitors |
| US7786121B2 (en) * | 2003-08-23 | 2010-08-31 | Vernalis (Oxford) Limited | Derivatives of hydroxamic acid as metalloproteinase inhibitors |
| US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| BRPI0516383A (pt) | 2004-12-21 | 2008-09-02 | Serono Lab | derivados cìclicos de sulfonil amino e o uso dos mesmos |
| WO2006079653A1 (en) | 2005-01-31 | 2006-08-03 | Laboratoires Serono S.A. | N-hydroxyamide derivatives and use thereof |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| EA013816B1 (ru) | 2005-09-01 | 2010-08-30 | Арес Трейдинг С.А. | Лечение неврита зрительного нерва |
| US8153166B2 (en) * | 2006-06-08 | 2012-04-10 | Chih-Hsiung Lin | Composition for prophylaxis or treatment of urinary system infection and method thereof |
| CA2922607C (en) | 2013-09-06 | 2022-08-30 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
| WO2016142833A1 (en) | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CA2979161A1 (en) * | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CN105384736B (zh) * | 2015-10-28 | 2018-11-02 | 南昌大学 | 一种ⅳ型胶原酶抑制剂及合成方法 |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| EP3694841A1 (en) | 2017-10-11 | 2020-08-19 | Aurigene Discovery Technologies Limited | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| JP7378394B2 (ja) | 2017-11-03 | 2023-11-13 | オーリジーン オンコロジー リミテッド | Ｔｉｍ－３およびｐｄ－１経路の二重阻害剤 |
| EA202090749A1 (ru) | 2017-11-06 | 2020-08-19 | Ориджен Дискавери Текнолоджис Лимитед | Способы совместной терапии для иммуномодуляции |
| CN108530378B (zh) * | 2018-05-29 | 2021-09-14 | 济南大学 | 一类含有噁二唑结构的氮原子双取代异羟肟酸类化合物、用途及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665753A (en) * | 1994-03-03 | 1997-09-09 | Smithkline Beecham Corporation | Cytokine inhibiting imidazole substituted hydroxamic acid derivatives |
| GB9404046D0 (en) * | 1994-03-03 | 1994-04-20 | Smithkline Beecham Corp | Novel compounds |
| US5703092A (en) * | 1995-04-18 | 1997-12-30 | The Dupont Merck Pharmaceutical Company | Hydroxamic acid compounds as metalloprotease and TNF inhibitors |
| JP2001507342A (ja) * | 1996-12-17 | 2001-06-05 | ワーナー−ランバート・コンパニー | 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用 |
| EP1064289A1 (en) * | 1998-03-18 | 2001-01-03 | Ariad Pharmaceuticals, Inc. | Heterocyclic signal transduction inhibitors, compositions containing them |
| JP2001031637A (ja) * | 1999-05-17 | 2001-02-06 | Fuji Chemical Industries Ltd | 新規なヒドロキサム酸誘導体 |
| US6448278B2 (en) * | 1999-12-23 | 2002-09-10 | Pfizer Inc. | Procollagen C-proteinase inhibitors |
| GB9930570D0 (en) * | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
-
2002
- 2002-02-22 GB GBGB0204159.8A patent/GB0204159D0/en not_active Ceased
-
2003
- 2003-02-20 US US10/504,317 patent/US7358265B2/en not_active Expired - Fee Related
- 2003-02-20 UA UA20040806941A patent/UA78275C2/uk unknown
- 2003-02-20 BR BR0307899-0A patent/BR0307899A/pt not_active IP Right Cessation
- 2003-02-20 DE DE60313292T patent/DE60313292T2/de not_active Expired - Lifetime
- 2003-02-20 CA CA2475867A patent/CA2475867C/en not_active Expired - Fee Related
- 2003-02-20 MX MXPA04008132A patent/MXPA04008132A/es active IP Right Grant
- 2003-02-20 AT AT03702791T patent/ATE360007T1/de active
- 2003-02-20 PL PL372268A patent/PL210773B1/pl unknown
- 2003-02-20 EP EP03702791A patent/EP1476438B1/en not_active Expired - Lifetime
- 2003-02-20 WO PCT/GB2003/000741 patent/WO2003070711A1/en active IP Right Grant
- 2003-02-20 EA EA200401095A patent/EA007609B1/ru not_active IP Right Cessation
- 2003-02-20 PT PT03702791T patent/PT1476438E/pt unknown
- 2003-02-20 CN CNB038089122A patent/CN100351245C/zh not_active Expired - Fee Related
- 2003-02-20 AU AU2003205910A patent/AU2003205910B2/en not_active Ceased
- 2003-02-20 JP JP2003569618A patent/JP4615864B2/ja not_active Expired - Fee Related
- 2003-02-20 SI SI200330870T patent/SI1476438T1/sl unknown
- 2003-02-20 DK DK03702791T patent/DK1476438T3/da active
- 2003-02-20 ES ES03702791T patent/ES2286404T3/es not_active Expired - Lifetime
- 2003-02-20 RS YUP-716/04A patent/RS51354B/sr unknown
- 2003-02-20 KR KR1020047012821A patent/KR101098614B1/ko not_active IP Right Cessation
-
2004
- 2004-08-09 IL IL163413A patent/IL163413A/en not_active IP Right Cessation
- 2004-08-10 HR HR20040725A patent/HRP20040725A2/hr not_active Application Discontinuation
- 2004-08-25 ZA ZA200406755A patent/ZA200406755B/en unknown
- 2004-09-14 NO NO20043846A patent/NO330772B1/no not_active IP Right Cessation
-
2006
- 2006-01-26 HK HK06101230A patent/HK1078583A1/xx not_active IP Right Cessation
-
2007
- 2007-07-13 CY CY20071100937T patent/CY1106730T1/el unknown
-
2008
- 2008-02-08 US US12/028,275 patent/US20080227833A1/en not_active Abandoned
-
2009
- 2009-10-14 US US12/588,372 patent/US20100035943A1/en not_active Abandoned
-
2010
- 2010-10-07 US US12/900,262 patent/US20110086893A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106730T1 (el) | Οξα - και θειαδιαζολες και η χρηση τους ως αναστολεις μεταλλοπρωτεϊνασης | |
| CY2019032I2 (el) | (+)-2-[1-(3-αιθοξυ-4-μεθοξυφαινυλ)-2-μεθυλσουλφονυλαιθυλ]-4-ακετυλαμινoϊσoϊνδoλινo-1,3-διonη: μεθοδοι χρησης και συνθεσεις αυτης | |
| CY1107525T1 (el) | Αναστολεiς μεταλλοπρωτεϊνασης | |
| CY1114284T1 (el) | Σουλφονυλοπυρρολες ως hdac αναστολεις | |
| CY1111050T1 (el) | Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων | |
| CY1112780T1 (el) | Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac | |
| BRPI0608886B8 (pt) | derivados de n-sulfonilpirróis e seus usos | |
| CY1112442T1 (el) | Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης | |
| CY1106640T1 (el) | Αναστολεις κρουζιπαϊνης και αλλων πρωτεασων κυστεϊνης | |
| CY1113314T1 (el) | (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης | |
| EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
| UY27972A1 (es) | Derivados de hidantoína | |
| CY1114916T1 (el) | Μεθοδοι | |
| NO20061157L (no) | 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer | |
| DE60234028D1 (de) | Hydantion-derivate als hemmer von matrix-metalloproteinasen | |
| CY1106104T1 (el) | Αναστολεις φαρναζυλτρανσφepασης | |
| NO20032788L (no) | Modafinil-forbindelse og cyklodekstrinblandinger | |
| NO20045675L (no) | Peptiddeformylaseinhibitorer | |
| CY1111432T1 (el) | Τετραϋδροκινολινες για χρηση ως διαμορφωτες της μιτοτικης κινητικης πρωτεϊνης eg5 | |
| NO20061316L (no) | Imidazopyndinderivater som induserbare NO-syntaseinhibitorer | |
| BRPI0415390A (pt) | compostos de pirazinona substituìda para o tratamento da inflamação | |
| DE60033809D1 (de) | Inhibitoren von metalloproteinasen | |
| EA200600601A1 (ru) | Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы | |
| ATE398617T1 (de) | Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase | |
| IS7441A (is) | Peptíðdeformýlasatálmar |